Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK inhibitors in rheumatoid arthritis-associated interstitial lung disease
jRCT1041230171Recruiting
- Sponsor
- National Hospital Organization
- Start
- Mar 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of tofacitinib, baricitinib, peficitinib, upadacitinib and filgotinib in rheumatoid arthritis (RA), interstitial lung disease (ILD) and Interstitial Lung Disease Rheumatoid Arthritis Related (RA-ILD), sponsored by National Hospital Organization. Primary endpoint: Change in RA-ILD imaging score. Started Mar 2024; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)interstitial lung disease (ILD)Interstitial Lung Disease Rheumatoid Arthritis Related (RA-ILD)
Beyond the preview
Go deeper on jRCT1041230171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041230171.